Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Linsitinib | 1 | uM | 9 | 312.50 | 200.50 | 295.00 | 336.50 | 0.8767 | 0.6769 |
| SK-BR-3 | Erlotinib | 0.31623 | uM | 9 | 312.50 | 200.50 | 407.00 | 336.50 | 1.2095 | 1.5800 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 375.00 | 336.50 | 1.1144 | 1.3121 | |
| SK-BR-3 | Linsitinib | 19.9526 | uM | 9 | 312.50 | 200.50 | 232.00 | 336.50 | 0.6895 | 0.2157 |
| SK-BR-3 | Linsitinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 378.00 | 336.50 | 1.1233 | 1.3369 |
| SK-BR-3 | Erlotinib | 10 | uM | 9 | 312.50 | 200.50 | 154.00 | 336.50 | 0.4577 | -0.2976 |
| SK-BR-3 | Erlotinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 203.00 | 336.50 | 0.6033 | 0.0167 |
| SK-BR-3 | 17-AAG | 0.0031623 | uM | 9 | 312.50 | 200.50 | 245.00 | 336.50 | 0.7281 | 0.3078 |
| SK-BR-3 | Erlotinib | 0.01 | uM | 9 | 312.50 | 200.50 | 502.00 | 336.50 | 1.4918 | 2.4165 |
| SK-BR-3 | Linsitinib | 0.01 | uM | 9 | 312.50 | 200.50 | 343.00 | 336.50 | 1.0193 | 1.0519 |
| SK-BR-3 | 17-AAG | 0.0001 | uM | 9 | 312.50 | 200.50 | 402.00 | 336.50 | 1.1947 | 1.5376 |
| SK-BR-3 | 17-AAG | 0.01 | uM | 9 | 312.50 | 200.50 | 159.00 | 336.50 | 0.4725 | -0.2669 |
| SK-BR-3 | Linsitinib | 10 | uM | 9 | 312.50 | 200.50 | 317.00 | 336.50 | 0.9421 | 0.8464 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 409.00 | 336.50 | 1.2155 | 1.5970 | |
| SK-BR-3 | Lapatinib | 1 | uM | 9 | 312.50 | 200.50 | 185.00 | 336.50 | 0.5498 | -0.1021 |
| SK-BR-3 | Lapatinib | 10 | uM | 9 | 312.50 | 200.50 | 109.00 | 336.50 | 0.3239 | -0.5578 |
| SK-BR-3 | Lapatinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 270.00 | 336.50 | 0.8024 | 0.4894 |
| SK-BR-3 | Linsitinib | 0.1 | uM | 9 | 312.50 | 200.50 | 325.00 | 336.50 | 0.9658 | 0.9090 |
| SK-BR-3 | Lapatinib | 0.031623 | uM | 9 | 312.50 | 200.50 | 184.00 | 336.50 | 0.5468 | -0.1086 |
| SK-BR-3 | 17-AAG | 0.031623 | uM | 9 | 312.50 | 200.50 | 154.00 | 336.50 | 0.4577 | -0.2976 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 291.00 | 336.50 | 0.8648 | 0.6465 | |
| SK-BR-3 | 0 | uM | 9 | 625.00 | 414.82 | 749.00 | 779.25 | 0.9612 | 0.9148 | |
| SK-BR-3 | 0 | uM | 9 | 625.00 | 414.82 | 789.00 | 779.25 | 1.0125 | 1.0275 | |
| SK-BR-3 | Erlotinib | 0.0033113 | uM | 9 | 625.00 | 414.82 | 771.00 | 779.25 | 0.9894 | 0.9767 |
| SK-BR-3 | 17-AAG | 0.001 | uM | 9 | 625.00 | 414.82 | 888.00 | 779.25 | 1.1396 | 1.3089 |